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Background: With the promise of disease modifying treatments, there is a need for more specific diagnosis and
prognosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Plasma biomarkers are likely to be
utilised to increase diagnostic accuracy and specificity of AD and cognitive decline.
Methods: Isobaric tags (iTRAQ) and proteomic methods were used to identify potential plasma biomarkers of MCI
and AD. Relative protein expression level changes were quantified in plasma of 411 cognitively normal subjects,
19 AD patients and 261 MCI patients. Plasma was pooled into 4 groups including normal control, AD, amnestic
single and multiple domain MCI (aMCI), and nonamnestic single and multiple domain MCI (nMCI). Western-blotting
was used to validate iTRAQ data. Integrated function and protein interactions were explored using WEB based
bioinformatics tools (DAVID v6.7 and STRING v9.0).
Results: In at least two iTRAQ replicate experiments, 30 proteins were significantly dysregulated in MCI and
AD plasma, relative to controls. These proteins included ApoA1, ApoB100, complement C3, C4b-binding
protein, afamin, vitamin D-binding protein precursor, isoform 1 of Gelsolin actin regulator, Ig mμ chain C region
(IGHM), histidine-rich glycoprotein and fibrinogen β and γ chains. Western-blotting confirmed that afamin was
decreased and IGHM was increased in MCI and AD groups. Bioinformatics results indicated that these dysregulated
proteins represented a diversity of biological processes, including acute inflammatory response, cholesterol transport
and blood coagulation.
Conclusion: These findings demonstrate that expression level changes in multiple proteins are observed in MCI and
AD plasma. Some of these, such as afamin and IGHM, may be candidate biomarkers for AD and the predementia
condition of MCI.
Keywords: Biomarkers, Isobaric tags for relative and absolute quantitation (iTRAQ), Plasma, Mild Cognitive Impairment,
Alzheimer’s disease, ProteomicsIntroduction
Alzheimer’s disease (AD) is the most common cause
of dementia and approximately one in eight people over
65 years old are at risk. AD is an age-related and
insidious-onset neurodegenerative disease [1]. Mild cog-
nitive impairment (MCI) is proposed to be a phase of* Correspondence: a.poljak@unsw.edu.au
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reproduction in any medium, provided the orcognitive decline intermediate between normal health
and dementia [2]. MCI patients may progress to AD,
vascular disease and other kinds of dementia. The diag-
nosis of MCI and AD depends on a combination of clin-
ical and neuropsychological tests, with no easy and
effective diagnostic methods for use in the early stages
of cognitive impairment. Early diagnosis may support
measures to prevent disease progression from MCI to AD,
and benefit the development of effective treatments. Sev-
eral previous studies have focused on this field and re-
ported some proteins as potential AD plasma biomarkerstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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published [6,7]. A few studies have chosen panels of spe-
cific proteins for analysis in the context of AD biomarkers
[8,9], however few studies have applied discovery-based
proteomics methods to the plasma of MCI subjects to
identify biomarkers of the pre-dementia stage of AD.
Obtaining plasma is less invasive than other techniques
such as lumbar puncture, and plasma is a body fluid widely
accepted for use in clinical testing. It reflects the full com-
plexity of body proteins in health and disease, containing
biomarkers relevant for prediction, diagnosis or further
investigation into the cause and effects of neurological
disorders. Despite the ease in obtaining plasma, a major
challenge associated with its analysis is its high com-
plexity. The relatively high abundance of proteins like
serum albumin and immunoglobulins, which together
constitute more than 85% of the total protein content,
masks the lower abundant proteins which may be po-
tential biomarkers. To overcome this problem, the high
abundance proteins must first be removed with the use
of affinity depletion columns [10,11].
Our objective was to examine the alteration in global
expression of proteins in the plasma of MCI and AD sub-
jects in comparison with cognitively normal subjects. The
iTRAQ approach was utilised to analyse immunodepleted
plasma samples from amnestic single and multiple do-
main MCI (aMCI), nonamnestic single and multiple do-
main MCI (nMCI), AD and cognitively normal subjects
to reveal candidate biomarkers. Pooled plasma from the
various groups was assayed and the iTRAQ experiments
repeated three times (three biological replicates), and run
twice (two technical replicates) by two dimensional liquid
chromatography (2D LC) tandem mass spectrometry (MS/
MS). It was expected that studying plasma proteins in
MCI and AD subjects using a discovery-based proteomics
method might identify potential new protein biomarkers
for neurodegenerative disease, and provide a screening
tool for identifying specific proteins to study in more de-
tail, as we have already begun to do [12].
Experimental procedures
Ethics statement and consent
Ethics committee approval was obtained from the
University of New South Wales (UNSW) and the South
East Sydney Area Health Service (SESAHS) ethics commit-
tees, and is in compliance with the Helsinki Declaration.
Written informed consent was obtained from patients and,
in the case of AD subjects, additionally from a significant
family member.
Subjects and samples
Plasma samples of aMCI (n = 147), nMCI (n = 114) and
cognitively normal subjects (n = 411) were collected from
the Wave 1 (baseline) of the Sydney Memory and AgeingStudy (MAS) (n = 1073), a population based longitudinal
study of non-demented older adults [13]. Plasma samples
from AD patients (n = 19), who were volunteers for a drug
trial of a cholinesterase inhibitor, were collected at the
Memory Clinic of the Department of Old Age Psychiatry of
the Prince of Wales Hospital. Patients met the NINCDS-
ADRDA (National Institute of Neurological and Communi-
cative Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association) criteria [14] for clinically determined
probable mild or moderate AD. Samples from all study
groups were collected using the same protocol. Fasting
plasma samples containing EDTA were aliquoted (100 μl)
into polypropylene tubes, stored at −80°C, and only thawed
immediately before assay.Clinical evaluation
The diagnosis of MCI used for this study was based on
international consensus criteria [15] as follows: (a) com-
plaint of decline in memory or other cognitive function
which may be self- or informant-reported; (b) cognitive
impairment on objective testing, i.e. not normal for age
as determined by performance on at least one test mea-
sure 1.5 SDs or more below published normative values
(or comparable standardised score compared to age and/
or education-matched samples); (c) participants did not
have a pre-existing diagnosis of dementia on entry to the
study, had an adjusted mini–mental state examination
(MMSE) score of ≥24 and did not meet DSM-IV (American
Psychiatric Association Diagnostic and Statistical Manual,
4th Edition) criteria [16] for possible or probable dementia;
(d) essentially normal function or minimal impairment in
IADLs defined by a total average score <3.0 on the inform-
ant rated B-ADL [17].
Two MCI subtypes [18] are defined according to the
following cognitive impairment profiles: amnestic single
and multiple domain (only memory domain impaired
and memory plus at least one non-memory domain im-
paired), non-amnestic single and multiple domain (one
non-memory domain impaired and more than one non-
memory domain impaired). The criterion for impaired
domain was met if at least one of the measures from the
domain was impaired, with a score 1.5 SD below norma-
tive data. The full list of domains, tests used for measuring
each domain, and the sources of normative data used to
determine impairment is presented in a previously pub-
lished paper [13].Sample preparation and immunodepletion
Individual plasma samples were pooled into four groups
according to the diagnosis (Table 1), comprising cognitively
normal, aMCI, nMCI and AD. Three aliquots (150 μl) of
pooled plasma from each group were immunodepleted in
each of three 5-plex iTRAQ experiments.
Table 1 Subject characteristics and iTRAQ reporter
ion labelling
Groups Normal aMCI nMCI AD
Subject No. 411 147 114 19
Mean age (SD) 77.9 (4.5) 79.3 (4.9) 78.2 (4.3) 73.8 (8.0)
% male 42.8 57.1 37.7 68.4
iTRAQ tag 113 114 115 116
aMCI, amnestic single and multiple domain MCI.
nMCI, nonamnestic single and multiple domain MCI.
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pleted using Multiple Affinity Removal Column (Hu-6,
4.6 × 50 mm, Agilent, Palo Alto, CA). These included al-
bumin, IgG, antitrypsin, IgA, transferrin and haptoglo-
bin. Manufacturer’s instructions were followed for all
steps. This kit also contains buffers for sample loading,
washing, eluting and regenerating the column. Prior to
chromatography, plasma samples were diluted five-fold
using Buffer A. Particulates from plasma were removed
using 0.22 μm spin filter (Millipore, Bedford, MA). Diluted
plasma (100 μl) was loaded for each chromatography
step at a flow rate of 0.25 mL/min and immunodeple-
tion was performed using an HP1090 HPLC system
(Agilent, Sydney, Australia). The flow-through fraction
containing low abundance proteins was collected between
1.50-6.50 minutes, and concentrated using Amicon Ultra
centrifugal filter devices (Millipore, Billerica, MA). The
filter device was spun at 5000 × g for 45 minutes at 4°C.
Protein assay, protein reduction and alkylation
The total protein concentration of low abundance proteins
from the immunodepletion column flow-through of each
subject group was determined using the Bicinchoninic acid
(BCA) total protein assay (Pierce, Rockford, IL). To remove
potentially iTRAQ incompatible buffer components, a por-
tion of each sample comprising 100 μg of total protein
was precipitated for two hours in chilled acetone (neat)
at −20°C. The protein pellet was then resuspended (20 μl
dissolving buffer, 45.5 mM NaHCO3) and 1 μl denaturant
SDS (2%) was added. Samples were then reduced with 2 μl
5 mM tris-(2-carboxyethyl) phosphine (TCEP) for one
hour at 60°C, and alkylated with 200 mM iodoacetamide
at ambient temperature for ten minutes to irreversibly
block cysteine groups.
Protein digestion and iTRAQ labelling
After reduction and alkylation, the proteins in each group
were digested overnight with trypsin (4.44 μg/10 μL) at
37°C. Three biological replicates of each group were di-
gested independently. Samples were then labelled with iTR
AQ reagents following the protocol provided by the vendor
(Applied Biosystems, Foster City, CA). Briefly, one vial of
iTRAQ labelling reagent (dissolved in neat isopropanol)was used per subject group. The entire contents of each
iTRAQ vial was added to each sample and incubated for
two hours at 37°C. The pH was then measured and ad-
justed to 7.5 by adding dissolution buffer (45.5 mM
NaHCO3). The iTRAQ labelled samples were then pooled
into a single vial. The experimental design for iTRAQ re-
porter ion sample labelling is shown in Table 1.
All solid phase extraction (SPE) sample clean-up steps
were carried out using a syringe pump (KD Scientific,
Holliston, MA) at a flow rate of 9.5 mL/hr. iTRAQ labelled
peptides were fractionated by strong cation exchange SPE
(Applied Biosystems, Foster City, CA), dried under vac-
uum and passed through a C18 SPE cartridge to desalt
the sample (Peptide MacroTrap, Michrom Bioresources,
Auburn, CA), eluted with 500 μl CH3CN : water : formic
acid (50:50:0.1, v:v:v), followed by 200 μl CH3CN. The flow-
through from the C18 step was then passed through an
Oasis SPE cartridge (Waters, Milford, MA) to maximise
sample recovery by capturing any peptides which may have
passed through the C18 SPE.
Two-dimensional liquid chromatography and
MS/MS analysis
2D LC was carried out according to a published ap-
proach [19,20]. Chromatography was carried out using an
LC Packings capillary HPLC system (Dionex, Amsterdam,
the Netherlands), comprising an UltiMate pump system,
Switchos valve unit and Famos autosampler. A portion of
the iTRAQ labelled peptide mixture (ca 5 μg) was injected
onto a strong cation exchange micro column (0.75 × ~ 20
mm, Poros S10, Applied Biosystems, Foster City, CA) and
eluted with 12 ammonium acetate elution steps (5, 10, 15,
20, 25, 30, 40, 50, 100, 250, 500 and 1000 mM). The eluent
was captured onto a C18 pre-column cartridge (Michrom
Bioresources, Auburn, CA). After a 10 min wash, the
pre-column was switched in-line to a capillary column
(10 cm) containing C18 reverse phase packing material
(Magic, 5 μ, 200 Å, Michrom Bioresources, Auburn, CA).
Peptides were eluted using a 75 min gradient of buffer A
(H2O:CH3CN of 98:2 containing 0.1% formic acid-buffer)
to buffer B (H2O:CH3CN of 20:80 containing 0.1% formic
acid-buffer) at ~300 nL/min. High voltage (2300 V) was ap-
plied through a low volume tee (Upchurch Scientific, Oak
Harbor, WA) at the column inlet and the outlet positioned
approximately 1 cm from the orifice of an API QStar Elite
hybrid tandem mass spectrometer (ABSciex, Forster City,
CA). Positive ions were generated by electrospray ionisation
(ESI) and the QStar operated in information-dependent ac-
quisition (IDA) mode. A time-of-flight (TOF) MS survey
scan was acquired (m/z 350–1700, 0.75 s) and the three lar-
gest multiply charged ions (counts > 20, charge state ≥ 2
and ≤ 4) sequentially selected by Q1 for MS/MS analysis.
Nitrogen was used as collision gas and an optimum colli-
sion energy automatically chosen (based on charge state
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to 2.5 s (m/z 65–2000).
Database searching, statistical analysis and bioinformatics
Protein identification and quantitation were performed
using the MS/MS data (WIFF files) and the Paragon al-
gorithm as implemented in Protein Pilot v2.0.1 software
(Applied Biosystems/MDS Sciex, Foster City, CA). The
database used was ipi. HUMAN. v 3.58. fasta [20]. Iden-
tification of proteins was only accepted with a Protein-
Pilot Unused Score of ≥1.3 (greater than 95% confidence
interval). The Paragon method uses the miscleavage fac-
tor to calculate the probability of missed cleavages. Most
commonly 1 or 2 missed cleavages are allowed. The Pro-
teinPilot Biological Modifications option was selected to
search for variable post-translational modifications (PTMs).
This includes a list of >220 PTMs to include in the search.
The modifications use the HUPO-PSI modification nomen-
clature. The only fixed modification used was iodoaceta-
mide alkylation of cysteine residues. Mass tolerances were
ca 50 ppm for the precursor and 0.2 Da for the fragment
ion masses. Autobias correction was used to correct for sys-
tematic bias in sample pooling. Only proteins identified in
all three iTRAQ experiments were further analysed. Quan-
titative data were exported into Excel (Microsoft, Bellevue,
WA) for further analysis.
Integrated function and protein interactions were ex-
plored using Web-based bioinformatics tools: Database
for Annotation, Visualisation and Integrated Discovery
(DAVID v6.7) [21,22] and Search Tool for the Retrieval
of Interacting Genes/Proteins (STRING v9) [23]. DAVID
bioinformatics resources consist of an integrated bio-
logical knowledgebase and analytic tools aimed at sys-
tematically extracting biological meaning from large gene/
protein lists. STRING is a meta-resource that aggregates
most of the available information on protein-protein as-
sociations, scores and weights, and augments it with
predicted interactions, as well as results of automatic
literature-mining searches. The full set of dysregulated
proteins in MCI and AD from iTRAQ results was en-
tered into DAVID for functional analysis and STRING
for the analysis of protein interaction. The background
set for DAVID analysis was the full homosapiens gen-
ome (default set in DAVID).
Western blot analysis
High abundance protein-depleted plasma samples were
electrophoretically separated on a 1D NuPAGE 4-12%
gradient gel (Invitrogen, Carlsbad, CA), with equal amounts
of total protein (15 μg) loaded in each lane. Prestained
markers were loaded in one lane to indicate approximate
molecular weight. The gel was electroblotted (10 V, 80 mA,
2 hr) onto a nitrocellulose membrane in semidry transfer
buffer (50 mM Tris HCl, 40 mM glycine, 1.3 mM SDS, 20%methanol, pH 9.2). Once the transfer was complete, the
nitrocellulose membrane was incubated in skim milk pow-
der solution (10% in 10 mM tris/HCl pH 7.5 containing
0.9% NaCl) containing the primary antibody. Immuno-
blotting was carried out with antibodies against afamin
(0.86 μg/ml, Abcam, Cambridge, UK) and Ig mμ chain
C region (Immunoglobulin heavy constant mu, IGHM)
(1:200 dilution, Abnova Coporation, Taibei, Taiwan), fol-
lowed by a secondary antibody (1:100,000 anti-rabbit
IgG and anti-mouse IgG, respectively) (Pierce, Rockford,
IL). Chemiluminescence blots were developed with 1:1
solution of Super Signal West Femto Luminol/Enhancer
and Stable Peroxide buffer (Pierce, Rockford, IL) and using
the manufacturer’s instructions. Chemiluminescence films
were scanned using a KODAK Gel Logic 100 Imaging Sys-
tem (Sydney, Australia). Western blot images were then
quantified using Labscan v3.00 software (Amersham Bio-
science, UK).Results
iTRAQ analysis of plasma proteins from aMCI, nMCI, AD
and cognitively normal subjects to detect differential
protein expression
Plasma protein expression profiles in MCI and AD were
analysed by comparing the results of three biological repli-
cates of the 5-plex iTRAQ experiment. Proteins identified
in the three iTRAQ replicates and their reporter ion ratios
relative to the control sample (reporter ion 113) are pre-
sented in Additional file 1: Table S1, Additional file 2:
Table S2 and Additional file 3: Table S3. Protein Pilot v2.0
identified and quantified a total of 93, 107 and 96 proteins
in the first, second and third biological replicates, respect-
ively. The results of three iTRAQ replicates are sum-
marised in Table 2.
In total, 145 unique proteins were identified, with a mini-
mum unused score of ≥1.3 (which indicates a >95% confi-
dence in correct sequence identification). A subset of 30
significantly dysregulated proteins (Table 3) were selected
for further analysis using bioinformatics tools, the selection
criteria being: 1) significant iTRAQ ratio alteration for a
particular protein (p value ≤ 0.05) in at least one MCI sub-
type or AD group, and 2) consistent trends of significant
alteration in at least two iTRAQ replicates. Thirty proteins
met the criteria, and Table 3 shows the iTRAQ results of
these proteins. Most ratios of dysregulated proteins were
between 0.75 and 1.25. A substantial proportion (26.7%) of
these proteins belonged to the apolipoprotein family. Pro-
tein level False Discovery Rate (FDR) analysis was carried
out using ProteinPilot v4. The number of proteins detected
at 5% FDR range from 93 to 111. Corresponding Protein-
Pilot confidence at 5% FDR ranges from 96.9% to 99.1%.
Corresponding unused ProtScore at 5% FDR ranges from
1.51 to 2.04.















iTRAQ 1 >1.3 (95) 93 352 5047 11908 72.1
iTRAQ 2 >1.3 (95) 107 357 7614 17211 76.4
iTRAQ 3 >1.3 (95) 96 301 6392 15789 71.8
*A ProteinPilot Unused score of >1.3 indicates >95% confidence in correct protein sequence identification.
¶Spectra identified ÷ total MS/MS spectra.
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proteins; DAVID v6.7
For an overview of the dysregulated proteins in MCI and
AD, functional analysis including molecular functions,
biological process and pathways were performed using
DAVID v6.7 tools (http://david.abcc.ncifcrf.gov/).
Molecular function analysis revealed that 29% of the pro-
teins dysregulated in MCI and AD had enzyme inhibitor
activity, 17% had cell surface binding, and other functions
included enzyme activator activity and sterol transport ac-
tivity. Biological process analysis showed the dysregulated
proteins are most often involved in the acute inflammatory
response, lipid transport, blood coagulation, cell activation
and complement activation (Table 4).
KEGG pathway analysis indicated that one significant
pathway of complement and blood coagulation was pres-
ent. Seven proteins are involved in this pathway including
A2M, complement component 3, complement component
4 binding protein, fibrinogen α chain (FGA), fibrinogen
beta chain (FGB), fibrinogen γ chain (FGG) and alpha-2-
antiplasmin.
Protein networks; STRING v9.0
Figure 1 shows the protein-protein interaction networks
generated by database and web-tool STRING 9.0 (http://
string-db.org). The 28 dysregulated proteins (see acro-
nyms in Table 3) determined from the iTRAQ experi-
ment were analysed using this molecular interaction tool.
Two functional modules are apparent in the network,
forming tightly connected clusters (Figure 1). The first
functional module includes apolipoprotein A1(ApoA1),
apolipoprotein A2(ApoA2), apolipoprotein B (ApoB), apo-
lipoprotein A4 (ApoA4), apolipoprotein D (ApoD) and
apolipoprotein C2 (ApoC2); the second includes histidine-
rich glycoprotein (HRG), FGA, FGB, FGG. The highest
numbers of connectivities are to ApoA1 and ApoA2.
Western blot results
Three replicates of western blot experiments were per-
formed to provide an independent comparison and valid-
ation of the iTRAQ experiments. One upregulated (IGHM)
and one downregulated (afamin) protein were chosen for
this comparison, and the reasons were (i) they are two of
the most significantly deregulated proteins in our list, with
ratios of up to 1.57 for IGHM and down to 0.69 forafamin), (ii) they have not previously been studied in MCI
and AD, and (iii) they may provide new insight into the
mechanism of disease. Western blot results confirmed that
IGHM was increased in MCI and AD groups (Figure 2),
and afamin was decreased in MCI and AD group (Figure 3).
Figures 2 and 3 also show the comparison of western blot
and iTRAQ outcomes of IGHM and afamin, and confirm
consistency of up regulation (ratio >1) or down regulation
(ratio <1) between the two experimental approaches, des-
pite slight differences between the mean values.
Validation in individual samples
A group of apolipoproteins, including ApoA1, ApoA2,
ApoB, ApoH, ApoJ, have been selected from iTRAQ
results and measured in individual samples, and the
data published [12]. Table 5 compares the average ratios
of these 5 apolipoproteins between disease and normal
groups in the iTRAQ pooled plasma samples and individ-
ual validation based on previous multiplex assay data,
using the same MAS Wave 1 study group [21]. These two
results were consistent and showed that the ApoA1,
ApoA2, ApoH were downregulated and ApoB and ApoJ
were upregulated in the MCI group.
Discussion
Quantitation of serum or plasma proteins using iTRAQ
analysis has recently been suggested as a suitable ap-
proach for the detection of biomarkers [24]. In a prelim-
inary proof-of-principle experiment, this current study
assessed whether this method could be suitable for the
detection of biomarkers useful for MCI and AD screening.
We identified 30 proteins for which expression levels, rela-
tive to normal controls, were significantly altered in pooled
MCI and AD plasma samples. Bioinformatics results in-
dicated that these dysregulated proteins represented a di-
versity of biological functions, including immunity and
inflammation, transportation of important regulatory bio-
molecules, blood coagulation and cell processes. Protein
association network analysis also revealed dysregulation of
a sizeable group of apolipoproteins and fibrinogen chains
with important biological functions.
Dysregulated proteins in MCI and AD
A large number of dysregulated proteins in our iTRAQ re-
sults are apolipoproteins, and bioinformatic results showed
Table 3 Dysregulated proteins in the plasma of MCI subtypes and AD, identified in three iTRAQ biological
replicate experiments
Accession No. Name (Acronym) Replicate aMCI: Normal PVal nMCI: Normala,b PVal AD: Normal PVal
IPI00855916.1 Transthyretin (TTR) 1 2.15 0 *** 1.15 0.05 1.57 0 ***
2 0.94 0.28 0.93 0.1 1.06 0.28
3 0.91 0.13 1.13 0 *** 1.19 0 ***
IPI00745089.2 alpha 1B-glycoprotein precursor (A1BG) 2 1.09 0.03 1.08 0.01 1.09 0.01
3 1 0.99 1.06 0.02 1.17 0 ***
IPI00477090.6 Ig mu chain C region (IGHM) 1 1.05 0.6 0.97 0.63 1.41 0 ***
2 1.48 0 *** 1.21 0.03 1.57 0 ***
3 1.41 0 *** 1 0.99 1.47 0 ***
IPI00022229.1 Apolipoprotein B-100 (APOB) 1 1.03 0.23 1.31b 0 *** 1.01 0.73
2 0.99 0.63 1.19b 0 *** 1.01 0.56
3 1.03 0.17 1.03b 0.05 1.02 0.18
IPI00032291.2 Complement C5 (C5) 1 1.04 0.5 1.24b 0 *** 0.99 0.82
2 1 1 1.14b 0 *** 0.99 0.8
IPI00292530.1 Inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) 1 1.09 0.17 1.3b 0.01 1.05 0.25
3 1.24 0.01 1.13b 0.05 1.05 0.27
IPI00026314.1 Isoform 1 of Gelsolin (GSN) 1 0.99 0.86 1.13b 0.03 1.04 0.41
2 1.07 0.11 1.14b 0 *** 1.04 0.24
3 1.15 0 *** 1.09b 0.02 0.95 0.31
IPI00019591.2 Complement factor B (CFB) 1 0.96 0.14 0.95 0.12 0.95 0.05
2 0.93 0.05 0.91 0 *** 0.94 0.1
3 0.96 0.29 0.95 0.03 0.9 0 ***
IPI00019943.1 Afamin (AFM) 1 0.94 0.32 0.69b 0 *** 0.95 0.25
2 0.97 0.5 0.83b 0 *** 0.99 0.8
3 0.69 0 *** 0.87b 0 *** 1.01 0.79
IPI00021727.1 C4b-binding protein alpha chain (C4BPA) 1 0.93 0.02 1.04 0.22 0.96 0.18
2 0.82 0.01 0.98 0.77 0.97 0.56
3 0.85 0 *** 0.8 0.01 0.82 0 ***
IPI00479116.1 Carboxypeptidase N subunit 2 (CPN2) 1 0.79 0 *** 0.86 0.05 0.83 0.01
2 0.57 0 *** 1.01 0.88 0.74 0 ***
IPI00022371.1 Histidine-rich glycoprotein (HRG) 1 0.99 0.85 0.66b 0 *** 1.01 0.75
2 1.1 0.07 0.86b 0.02 1.07 0.07
3 0.87 0.01 0.95 0.15 0.96 0.2
IPI00006662.1 Apolipoprotein D (APOD) 1 0.99 0.92 1.03 0.67 0.83 0.01
3 0.71 0 *** 1.05 0.18 1.06 0.19
IPI00478003.1 Alpha-2-macroglobulin (A2M) 1 0.99 0.42 0.98 0.21 0.92 0 ***
2 1.06 0 *** 0.98 0.11 1.04 0.02
3 1.13 0 *** 0.99 0.44 0.9 0 ***
IPI00021841.1 Apolipoprotein A-I (APOA1) 1 1.38 0 *** 1.05 0.04 1.13 0 ***
2 0.51 0 *** 0.81 0 0.63 0 ***
3 0.66 0 *** 1.03 0.07 1.45 0 ***
IPI00021854.1 Apolipoprotein A-II (APOA2) 1 1.31 0 *** 0.81 0.01 0.85 0 ***
2 0.5 0 *** 0.91 0.05 0.81 0 ***
3 0.53 0 *** 1.06 0.13 0.98 0.68
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Table 3 Dysregulated proteins in the plasma of MCI subtypes and AD, identified in three iTRAQ biological
replicate experiments (Continued)
IPI00304273.2 Apolipoprotein A-IV (APOA4) 1 1.21 0 *** 0.99 0.8 0.97 0.39
2 0.72 0 *** 0.96 0.28 0.83 0 ***
3 0.67 0 *** 0.99 0.85 1.11 0 ***
IPI00021856.3 Apolipoprotein C-II (APOC2) 1 1.49 0.05 1.07 0.68 1.01 0.96
2 0.55 0.01 0.76 0.02 0.61 0.01
3 0.42 0.02 0.7 0.16 0.97 0.92
IPI00298828.3 Beta-2-glycoprotein 1 (APOH) 1 1.01 0.91 0.95 0.23 0.89 0.05
2 1.15 0 *** 0.97 0.43 1.18 0 ***
3 0.8 0 *** 0.97 0.5 0.87 0.01
IPI00783987.2 Complement C3 (C3) 1 0.97 0.07 0.94 0 *** 0.93 0 ***
2 1.01 0.64 0.95 0 *** 0.98 0.24
3 1.14 0 *** 1.01 0.24 0.92 0 ***
IPI00400826.1 Clusterin isoform 1 (CLU) 1 1.1 0.16 1 0.99 1.05 0.36
2 0.92 0.13 0.93 0.07 1.01 0.91
3 0.81 0.02 0.92 0.04 1.14 0.02
IPI00021885.1 Isoform 1 of Fibrinogen alpha chain (FGA) 1 0.94 0 *** 0.93 0 *** 1 0.88
2 1.01 0.76 0.89 0 *** 1.07 0 ***
3 1.15 0 *** 0.95 0.01 1.01 0.76
IPI00298497.3 Fibrinogen beta chain (FGB) 1 0.97 0.15 0.98 0.31 1.01 0.71
2 1.01 0.79 0.92 0 *** 1.05 0.01
3 1.16 0 *** 0.96 0.05 0.96 0.04
IPI00877792.1 Fibrinogen gamma chain (FGG) 1 1.1 0 *** 0.99 0.65 1.09 0 ***
2 0.85 0 *** 0.88 0 *** 0.91 0 ***
3 1.01 0.78 0.91 0 *** 0.92 0 ***
IPI00742696.2 vitamin D-binding protein precursor (GC) 1 1.01 0.83 1 0.88 1.04 0.19
2 0.27 0 *** 0.44 0 *** 0.27 0 ***
3 0.68 0 *** 0.98 0.44 1.07 0.04
IPI00641737.1 Haptoglobin-related protein (HPR) 1 0.87 0 *** 1.08 0.03 0.95 0.23
2 1.1 0 *** 1.06 0.03 1.06 0.05
3 1.07 0.11 0.96 0.27 1.01 0.77
IPI00896413.1 Inter-alpha-trypsin inhibito heavy chain H4 (ITIH4) 1 1.12 0.04 0.77 0.08 0.9 0.21
2 0.94 0.14 0.97 0.25 0.94 0.05
3 0.96 0.24 0.95 0.08 0.93 0.02
IPI00884926.1 Orosomucoid 1 precursor (ORM1) 2 0.85 0 *** 1.03 0.37 0.92 0.1
3 0.59 0 *** 1 0.98 1.07 0.05
IPI00550991.3 Alpha-1-antichymotrypsin (SERPINA3) 1 1.21 0 *** 1.05 0.15 1.17 0 ***
2 0.83 0 *** 0.93 0.05 0.87 0 ***
3 0.99 0.91 1 0.98 1.11 0 ***
IPI00879231.1 Alpha-2-antiplasmin (SERPINF2) 2 0.89 0.25 1.25 0 *** 1 0.99
3 0.86 0.05 1.21 0.01 1.05 0.53
aThis column represents nonamnestic MCI, with either single or multiple domains affected. The data are single and multiple domain unless otherwise indicated.
bNonamnestic multiple domain MCI (nmdMCI) data. Boldface data, P<0.05. ***P < 0.001. aMCI, amnestic single and multiple domain MCI. nMCI, nonamnestic
single and multiple domain MCI. The IPI human database was used during ProteinPilot processing.
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Table 4 Functional classification of dysregulated proteins in mild cognitive impairment and Alzheimer’s disease using
DAVID bioinformatics tool
Enrichment score¶ Protein count P value Benjamin
Biological process Acute inflammatory response 9.6 8 2.5E-11 6.1E-9
Blood coagulation 4.19 4 3.1E-4 5.2E-3
Cell activation 4.19 4 1.6E-2 3.3E-2
Lipid transport 3.35 5 3.4E-5 1.7E-3
Complement activation 2.45 3 6.6E-4 8.9E-3
Molecular function Enzyme inhibitor activity 6.66 8 1.5E-8 3.5E-7
Cell surface binding 4.19 5 3.6E-8 5.0E-7
Enzyme activator activity 3.35 4 7.4E-3 3.7E-2
Sterol transporter activity 3.35 3 1.3E-4 9.0E-4
Unclassified 7
¶The full human genome was used as the reference list [21,22]. The classification stringency was set to medium.
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teins. Recently, animal model and clinical studies have also
suggested that apolipoproteins are involved in neurodegen-
erative processes in AD [25-28]. Several apolipoproteins
were therefore selected for further validation in individual
plasma samples using multiplex analysis. These results have
been published [12].
In this study, FGA, FGB and FGG were identified as
dysregulated proteins in MCI and AD. STRING proteinFigure 1 Association networks of dysregulated proteins using STRINGconnections also revealed them to be components of a
functional module. Fibrin is the primary protein compo-
nent of a blood clot. Its inactive precursor, fibrinogen,
circulates in the blood as a large complex molecule of
340 kDa. Under normal circumstances, fibrinogen is ex-
cluded from the brain by the blood–brain barrier, but it
has been found to accumulate in the extravascular space
over time as AD pathology progresses [29-31]. Elevated
fibrinogen levels are reported to be associated withv9.0.
Figure 2 Comparison of western blot analysis and iTRAQ
results for IGHM.
Table 5 Comparison of average disease/normal iTRAQ
ratios for apolipoproteins on pooled plasma with
individual samples assayed by ELISA multiplex assays
iTRAQ* Multiplex assay§
aMCI:Normal nMCI:Normal AD:Normal MCI:Normal
ApoA1 0.85 0.96 1.07 0.91
ApoA2 0.78 0.93 0.88 0.94
ApoB 1.02 1.18 1.01 1.06
ApoH 0.99 0.96 0.98 0.91
ApoJ 0.94 1.10 1.07 1.10
*average ratios of three iTRAQ replicates.
§ratios of the mean values of apolipoprotein levels assayed in MCI and Normal
groups using individual plasma samples, as detailed in Song et al. [12].
Song et al. Proteome Science 2014, 12:5 Page 9 of 13
http://www.proteomesci.com/content/12/1/5increased risk for AD and dementia [32,33]. An in vitro
study recently suggested that the interaction between Aβ
and fibrinogen modifies fibrinogen’s structure which may
then lead to abnormal fibrin clot formation and vascular
abnormalities in AD [34].
Consistently up-regulated proteins observed in the MCI
and/or AD group(s) and in all three biological replicate
runs include IGHM, inter-alpha-trypsin inhibitor heavy
chain H1(ITIH1), transthyretin (TTR) and gelsolin. ITIH1
is one of the heavy chains of a serine protease inhibitor
that may serve to carry hyaluronan in plasma, and plays
a role in inflammation and carcinogenesis [35]. SomeFigure 3 Comparison of western blot analysis and iTRAQ results
for afamin.research suggested that ITIH1 may be related to the inci-
dence of Bipolar disorder [36] and human solid tumors
[35]. The role of ITIH1 in MCI and AD has not been fully
studied. TTR is a carrier protein which transports thyroid
hormones in the plasma and CSF, and also transports ret-
inol in the plasma. In the CNS, TTR also interacts with
Aβ, and it has been suggested that it protects against Aβ
deposition [37]. One recent study reported the opposite
results, finding that TTR levels in plasma were signifi-
cantly lower in AD subjects [38]. Gelsolin is a cytoskeletal
protein that presents both intracellularly and extracellu-
larly, and also binds to Aβ and inhibits the fibrillization of
Aβ [39,40]. One study showed that plasma gelsolin levels
were decreased in AD subjects [41]. Only a handful of
studies examined TTR and gelsolin levels in AD, and so far
no definite conclusion can be drawn. More research, espe-
cially large population-based studies, is needed in this area.
There were 6 consistently down-regulated proteins of
MCI and/or AD group in three biological runs, includ-
ing C4b-binding protein alpha chain (C4BPA), comple-
ment factor B (CFB), apolipoprotein D (ApoD), afamin,
carboxypeptidase N subunit 2 (CPN2) and histidine-rich
glycoprotein (HRG). Along with a single beta chain, seven
C4BPA assemble into the predominant isoform of C4b-
binding protein (C4BP), a complement inhibitor that con-
trols activation of the classical pathway of complement
activation. C4BP accumulates in Aβ plaques of AD brains
[42-44], and binds with Aβ1-42 peptide [43]. CFB is a
component of the alternative pathway of complement ac-
tivation. Our results support the possibility that comple-
ment regulatory proteins are involved in the pathogenesis
of AD. ApoD is localised in Aβ plaques of AD brains [45].
Some studies have shown that ApoD expression is dysreg-
ulated in AD brains [46-48]. Carboxypeptidase N (CPN) is
a zinc metalloprotease in plasma, containing two enzy-
matically active small subunits (CPN1) and two large sub-
units (CPN2) [49]. As a major regulator of inflammation,
CPN cleaves carboxy-terminal arginines and lysines from
peptides such as complement anaphylatoxins (C3a, C5a),
kinins and creatine kinase [50]. However, the role of CPN
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agulation [51], and also plays a role in inflammation and
immunity [52]. The role of HRG in AD has not been fully
investigated, and only one study reported that HRG was
decreased in AD sera [53].
The age of our AD group was slightly younger than
the MCI group and there were more male patients in
the AD group. This may be a limitation of this study, but
the impact of disease on the proteomic results is probably
more significant than the age and sex. In our previously
published work [12], which aimed to validate iTRAQ apo-
lipoprotein results in individual samples, differences in
apolipoprotein expression level withstood covariance for
age and sex, as well as several other population variables
such as years of education, APOE ε4 carrier status, and
hypolipidaemic medications [12]. Moreover, the ratios of
some proteins identified in this study are not consistent in
all three biological replicates. This may be due to the
modest ratio changes of some of these proteins in MCI
and AD. However using other quantitative methods to
measure this group of proteins in large samples may be
promising, and the iTRAQ method has proved to be a
useful screening tool.
Afamin and cognitive decline
It was found in this study that the oxidative stress-
associated protein afamin was down-regulated in pooled
MCI and AD plasma using both iTRAQ and western blot
analysis. To our knowledge, this is the first report of afamin
downregulation in MCI and AD plasma. Human plasma
afamin (α-albumin, α1T-glycoprotein) is the fourth mem-
ber of the albumin gene family that also includes albumin,
α -fetoprotein and vitamin D-binding protein. Interestingly,
like afamin, vitamin-D binding protein is also downregu-
lated in our list of iTRAQ deregulated proteins (Table 3).
A recent study revealed that afamin is synthesised in the
endothelial cells of the blood–brain barrier (BBB) and plays
a role in vitamin E transport in an in vitro model of the
BBB [54]. Vitamin E belongs to the family of nonenzymatic
antioxidants and is bound to afamin, its specific carrier
protein in plasma and extravascular fluids [55,56]. Vitamin
E is an important fat-soluble antioxidant and plays a crucial
role in protecting against oxidative damage and disease
[57]. Oxidative stress has been implicated in the inflamma-
tory reaction seen in AD brain. New gene chip technology
demonstrates that vitamin E deficiency can have a strong
impact on gene expression in the hippocampus [58], one
of the earliest brain regions to be affected in AD.
To date the role of dietary vitamin intake in AD has
been inconclusive, although it is generally accepted that
levels of plasma antioxidants, including vitamin levels, are
lower in AD [59-61]. Some clinical studies suggest that
Vitamin E intake might delay AD progression [62]. The
Chicago Health and Ageing Project showed that increaseddietary vitamin E intake (not from vitamin supplements)
correlated with lowered AD risk [63]. In the Rotterdam
Study, individuals who reported higher intakes of vitamins
C and E at baseline had a lower incidence of AD [64].
Consequently this area deserves more research attention,
particularly with the use of large scale population based
studies.
Furthermore, several other proteomic studies have iden-
tified afamin as a potential biomarker in other disorders,
including simian immunodeficiency virus (SIV) induced
central nervous system disease [10], ovarian cancer [65],
congenital disorders of glycosylation [66] and Down syn-
drome [67]. Thus alterations in afamin are not specific to
neurodegenerative disease and quantitative changes are
observed in other disorders as well. However, from the
standpoint of clinical use, afamin could be integrated with
other measures in a potentially multipronged approach to
diagnostic, prognostic and aetiologic studies. The specifi-
city of afamin might be improved in a test which includes
multiple markers, and this kind of “multiplexed” approach
may be necessary in complex multifactorial conditions/
diseases such as MCI and AD.
IGHM and cognitive decline
IGHM gained our attention because it had relatively high
fold changes in MCI and AD groups in comparison with
other dysregulated proteins (Table 3). Both iTRAQ and
western blot data showed that IGHM increased in MCI
and AD relative to normal plasma. Our results are consist-
ent with published data about the activation of the im-
mune system in AD. Upregulation of inflammation in AD
and MCI is recognised both in the CNS and in plasma
[68]. A typical immunoglobulin is composed of two identi-
cal heavy chains and two identical light chains joined by
disulfide bonds. Each Ig heavy chain has an N-terminal
variable region containing the antigen-binding site and
a C-terminal constant (C) region. The IGHM gene en-
codes the C region of the mu heavy chain, which defines
the IgM isotype. Human natural anti-Aβ antibodies are
present in both IgG and IgM repertoire [69]. Aβ binding
antibodies are present in healthy humans and AD patients
[70,71]. IgM anti-Aβ antibodies showed higher specific ac-
tivity for Aβ than IgG anti- Aβ antibody [69], and the abil-
ity to clear cerebral Aβ without entering the brain of a
mouse model of AD [72]. One recent study found that the
levels of plasma Aβ1-42 autoantibodies in patients with
MCI that progressed to AD, were significantly higher than
in cognitively normal controls, but not so for MCI stable
cases [73]. Aβ antibody titers were negatively correlated
with cognitive status such that more cognitively impaired
individuals tended to exhibit higher anti-Aβ IgG titers [71].
Development of immunotherapeutic reagents for AD is
based on the expression of specific proteolytic activity by
naturally occurring immunoglobulins [74], and hydrolysis
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induce increased Aβ clearance from the brain [75].
In conclusion, iTRAQ was chosen as a screening tool
in this study, to identify interesting candidate proteins as
biomarkers of MCI and AD. The function and interaction
of dysregulated proteins was studied using bioinformatics
tools. 28 proteins were found dysregulated in plasma of
MCI and AD. Bioinformatic results showed the dysregu-
lated proteins are most often involved in the acute inflam-
matory response, cholesterol transport, blood coagulation
and complement activation. Western blot was used to fur-
ther validate the change of afamin and IGHM in plasma
of MCI and AD. iTRAQ and western blot results both
confirmed that afamin was down-regulated and IGHM
was up-regulated in MCI and AD. These preliminary re-
sults suggest that plasma is a rich source for studying
plasma biomarkers of MCI and AD and that iTRAQ pro-
teomics is an excellent screening and discovery tool. The
data presented here includes proteins which have not
previously been studied in the context of MCI or AD, and
may represent excellent targets for a multiplexed bio-
marker assay.
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